Ningaraj Nagendra S, Rao Mamatha, Black Keith L
BBB and Drug Delivery Research Group, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 110 George Burns Road, Davis Research Building Room 2100, Los Angeles, CA 90048, USA.
Drug News Perspect. 2003 Jun;16(5):291-8. doi: 10.1358/dnp.2003.16.5.878815.
Even though the blood-brain tumor barrier (BTB) is more permeable than the blood-brain barrier (BBB), the BTB still significantly restricts the delivery of anticancer drugs to brain tumors. Brain tumor capillaries that form the BTB, however, express certain unique protein markers that are absent or barely detectable in normal brain capillaries. We were able to biochemically modulate one such protein marker, the calcium-dependent potassium (K(Ca)) channel, by using a specific K(Ca) channel agonist, NS-1619, to obtain sustained enhancement of selective drug delivery, including molecules of varying sizes, to tumors in rat syngeneic and xenograft brain tumor models. Immunolocalization and potentiometric studies showed increased K(Ca) channel distribution on tumor cells compared with normal cells, suggesting that tumor cell-specific signals might induce overexpression of K(Ca) channels in capillary endothelial cells, leading to increased BTB permeability. We also demonstrated that the cellular mechanism for K(Ca) channel-mediated BTB permeability increase is due to accelerated formation of pinocytotic vesicles, which can transport therapeutic molecules across the BTB. This concept was investigated by using NS-1619 to facilitate increased delivery of carboplatin to brain tumor leading to enhanced survival in rats with brain tumors. Additionally, we showed that K(Ca) channel modulation resulted in enhanced permeability to macromolecules, including Her-2 monoclonal antibody and green fluorescent protein-adenoviral vectors, in a human, primary brain-tumor xenograft model. Therefore, K(Ca) channels are a potential, promising target for biochemical modulation of BTB permeability to increase antineoplastic drug delivery selectively to brain tumors.
尽管血脑肿瘤屏障(BTB)比血脑屏障(BBB)具有更高的通透性,但BTB仍显著限制抗癌药物向脑肿瘤的递送。然而,构成BTB的脑肿瘤毛细血管表达某些独特的蛋白质标志物,这些标志物在正常脑毛细血管中不存在或几乎检测不到。我们能够通过使用特定的钙依赖性钾(K(Ca))通道激动剂NS-1619对一种这样的蛋白质标志物进行生化调节,以在大鼠同基因和异种移植脑肿瘤模型中实现对包括不同大小分子在内的肿瘤的选择性药物递送的持续增强。免疫定位和电位测定研究表明,与正常细胞相比,肿瘤细胞上K(Ca)通道分布增加,这表明肿瘤细胞特异性信号可能诱导毛细血管内皮细胞中K(Ca)通道的过表达,从而导致BTB通透性增加。我们还证明,K(Ca)通道介导的BTB通透性增加的细胞机制是由于胞饮小泡形成加速,胞饮小泡可将治疗分子转运穿过BTB。通过使用NS-1619促进卡铂向脑肿瘤的递送增加,从而提高脑肿瘤大鼠的存活率,对这一概念进行了研究。此外,我们表明,在人原发性脑肿瘤异种移植模型中,K(Ca)通道调节导致对大分子(包括Her-2单克隆抗体和绿色荧光蛋白腺病毒载体)的通透性增强。因此,K(Ca)通道是生化调节BTB通透性以选择性增加抗肿瘤药物向脑肿瘤递送的一个潜在的、有前景的靶点。